SecurityBSE:532978 / BAJAJ FINSERV LTD.
Institutional Owners0

Institutional Stock Ownership and Shareholders

BAJAJ FINSERV LTD. (BSE:532978) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
BAJAJ FINSERV LTD. (BSE:532978) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

An evening walk down Dalal Street | Pain continues on market, Sensex sheds 169 pts, Nifty gives up 11,250; midcaps fall

12h moneycontrol
Equity benchmarks ended a volatile trading day on a negative note as consumer names as well as banks weighed. The Nifty ended below 11,250-mark, while the Sensex shed a little over 160 points. Rupee heading towards its low points also dented sentiment on the market.

D-Street Buzz: Nify FMCG Media down 2% dragged by ITC, Hathway; RattanIndia Power zooms 20%

2018-09-11 moneycontrol
It is yet another afternoon session for the bears as the Indian stock market continues to trade lower this Tuesday afternoon extending the morning loses with the Nifty50 down 101 points and is trading at 11,336 while the Sensex is trading lower by 316 points at 37,605. (2-0)

D-Street Buzz: SBI gains 2% as Nifty PSU bank outperforms; Axis Bank most active, Hathway falls 4%

2018-09-11 moneycontrol
The Indian stock market continues to remain weak this Tuesday afternoon with the Nifty50 down 30 points and is trading at 11,407 while the Sensex is trading lower by 102 points at 37,819. (2-0)

D-Street Buzz: PSU banks gains led by SBI, Andhra Bank; FMCG stocks fall with ITC down 2%

2018-09-11 moneycontrol
The Indian benchmark indices are trading on a flat to negative note this Tuesday morning with the Nifty50 trading at 11,433, down 5 points while the Sensex is trading lower by 5 points at 37,916. (1-0)

Stocks slump on trade war

2018-09-10 thehindubusinessline
The escalating tariff war between the US and China had a ripple effect on Indian financial markets on Monday, roiling equity and forex markets alike.